Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Clinical trial NCT03631732 · COMPLETED
Trial details
- NCT number
- NCT03631732
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-28
- Primary completion
- 2019-08-12
- Enrollment
- 496
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.